VIA Pharmaceuticals, Inc. is a biotechnology company, which engages in the development of compounds for the treatment of cardiovascular diseases. The company is headquartered in San Francisco, California and currently employs 6 full-time employees. The company went IPO on 2000-04-18. The Company’s lead compound, VIA-2291, targets an unmet medical need of reducing atherosclerotic plaque inflammation, which is an underlying cause of atherosclerosis and its complications. Atherosclerosis is a cardiovascular disease that results from chronic inflammation and the build-up of plaque in arterial blood vessel walls. The Company’s clinical development strategy integrates several technologies to provide clinical proof-of-concept, as early as possible in the clinical development process. These technologies include the measurement of biomarkers, medical imaging of the coronary and carotid vessel walls to evaluate the plaque characteristics, and atherosclerotic plaque bioassays.
Follow-Up Questions
¿Cuál es el ratio P/E de VIA Pharmaceuticals Inc (VIAP)?
El ratio P/E de VIA Pharmaceuticals Inc es 0
¿Quién es el CEO de VIA Pharmaceuticals Inc?
Dr. Lawrence Cohen es el President de VIA Pharmaceuticals Inc, se unió a la empresa desde 2007.
¿Qué tal es el rendimiento del precio de la acción VIAP?
El precio actual de VIAP es de $0, ha decreased un 0% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de VIA Pharmaceuticals Inc?
VIA Pharmaceuticals Inc pertenece a la industria Biotechnology y el sector es Health Care
¿Cuál es la capitalización bursátil de VIA Pharmaceuticals Inc?
La capitalización bursátil actual de VIA Pharmaceuticals Inc es $0
